Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Fig. 4

Elacestrant inhibits the growth of ER+ patient-derived xenograft (PDX) models that represent CDK4/6i resistance. Mean tumor volumes (n = 6–10/arm) ± SEM of PDX-R1 (a, top) and WHIM43 (b, top). Percent change in tumor volumes from baseline for individual tumors from PDX-R1 at the end of study (a, bottom) and WHIM43 at day 55 (b, bottom). For the PDX-R1 model, asterisks represent significant differences between drug-treated and vehicle-treated groups at the end of the study. For the WHIM43 model, statistical analysis of drug-treated groups vs vehicle-treated groups was performed on the day the vehicle-treated groups were taken down (day 55) (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). c Western blot analysis of indicated proteins from tumors harvested 4 h post-last dose in the PDX-R1 model. d Western blot analysis of indicated proteins from tumors harvested 4 h post-last dose in the WHIM43 model. e Mean tumor volumes of ST941-HI PDX palbo-naive (P0) and ST941-HI PDX palbo-treated for > 150 days (P3) treated with a combination of fulvestrant and palbociclib, and single-agent elacestrant (in P3 only)

Back to article page